Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6273 posts found.

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024 Medical Communications EMA, GSK, Jemperli, Oncology, endometrial cancer

GSK has announced that the European Medicines Agency (EMA) has accepted the application to expand the use of Jemperli (dostarlimab) …
News

Sarepta Therapeutics gains expanded FDA approval for DMD treatment

June 21, 2024 Medical Communications DMD, Musculo-skeletal disorder, Sarepta Therapeutics

Sarepta Therapeutics has announced that the US Food and Drug Administration (FDA) has approved an expansion to the labelled indication …
News

FDA approves AbbVie’s Skyrizi for UC treatment

June 20, 2024 Medical Communications AbbVie, FDA, Gastrointestinal tract, UC, ibd

AbbVie has announced that the US Food and Drug Administration (FDA) has approved Skyrizi (risankizumab-rzaa) for the treatment of adult …
News

EC grants marketing authorisation to Sobi’s Altuvoct for haemophilia A treatment

June 19, 2024 Medical Communications Altuvoct, EC, EMA, Haematology, haemophilia a, sobi

Sobi has announced that the European Commission (EC) has granted marketing authorisation for Altuvoct (efanesoctocog alfa) for the treatment and …
News

FDA approves Merck’s Capvaxive for prevention of pneumococcal disease

June 18, 2024 Medical Communications Capvaxive, FDA, Infections and infestations, Merck, pneumonia

Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …
News

AstraZeneca’s Imfinzi approved in US for endometrial cancer treatment

June 17, 2024 Medical Communications AstraZeneca, Imfinzi, Oncology, chemotherapy, endometrial cancer

AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) in combination with carboplatin and …
News

CytoSorbents announces EU launch and availability of PuriFi blood pump

June 14, 2024 Medical Communications CytoSorbents, EU, Haematology, PuriFi, blood pump

CytoSorbents Corporation has announced the launch and immediate availability of its PuriFi haemoperfusion machine in the EU following its approval …
News

Tracon shares data from phase 2 trial for glioblastoma treatment

June 12, 2024 Medical Communications Oncology, Tracon Pharmaceuticals, clinical tria, clinical trial, glioblastoma

Tracon Pharmaceuticals has announced the publication of its phase 2 clinical data for its DNA damage repair inhibitor drug candidate, …
News
robina-weermeijer-ihfopazzjhm-unsplash_5

FDA accepts Eisai’s Leqembi sBLA for early AD treatment

June 11, 2024 Medical Communications Alzheimer's, Biogen, FDA, Neurology, sBLA

Eisai and Biogen have announced that the US Food and Drug Administration (FDA) has accepted Eisai’s supplemental biologics license application …
News

Santhera announces Early Access Program by partner Sperogenix for DMD treatment

June 11, 2024 Medical Communications DMD, Musculo-skeletal disorder, early access, muscular dystrophy, santhera

Santhera Pharmaceuticals has announced that its partner Sperogenix Therapeutics has launched a paid-for Early Access Program (EAP) for Agamree (vamorolone) …
News

GSK’s Arexvy vaccine approved by FDA for RSV prevention in adult patients

June 10, 2024 Medical Communications FDA, GSK, Immunology, Vaccine

GSK has announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) …
News
yunus-tug-lnfgdbcajxu-unsplash

FDA approves Geron’s Rytelo for treatment of MDS with transfusion-dependent anaemia

June 7, 2024 Medical Communications FDA, Geron, Haematology, anaemia, mds

Geron Corporation has announced that the US Food and Drug Administration (FDA) has approved Rytelo (imetelstat) for the treatment of …
News

AbbVie initiates phase 3 multiple myeloma trial

June 6, 2024 Medical Communications ABBV-383, AbbVie, Oncology, clinical trial, multiple myeloma

AbbVie has announced that it has dosed the first patient in its phase 3 CERVINO trial, which aims to assess …
News

Quince Therapeutics gains FDA Fast Track Designation for EryDex System

June 4, 2024 Medical Communications EryDex, FDA, Quince Therapeutics, Rare Diseases, fast track designation

Quince Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for its EryDex …
News

Oryzon Genomics announces publication of phase 2a ALICE trial results

June 4, 2024 Medical Communications AML, Oncology, Oryzon genomics, acute myeloid leukaemia, clinical trial

Oryzon Genomics has announced that the final results from its phase 2a ALICE study have been published online in The …
News

Latest content

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024

AskBio initiates phase 2 Parkinson’s trial recruitment

June 26, 2024

AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment

June 25, 2024

ILiAD Biotechnologies announces collaboration with Emmes Group on phase 3 pertussis vaccine trial

June 25, 2024

GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment

June 24, 2024